Modulation of apoptosis by HIV protease inhibitors.
Advances in treatment have transformed the Human Immunodeficiency Virus (HIV) infection from a progressive and ultimately fatal disease to one that can be managed effectively by chronic suppressive antiretroviral therapy. The drugs now used to treat HIV infection not only inhibit viral replication but also have effects on cellular metabolism and homeostasis. Of particular interest to cellular immunologists, members of the HIV Protease Inhibitor (PI) class of antiretroviral agents possess intrinsic immunomodulatory and antiapoptotic properties. This review focuses on the development and use of PI together with their impact on HIV disease, immunity, and apoptosis.
Phenix
B N
BN
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.
Cooper
C
C
Owen
C
C
Badley
A D
AD
D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000502:physiology; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D017320:HIV Protease Inhibitors / Q000276:immunology / Q000493:pharmacokinetics / Q000494:pharmacology*; D015497:HIV-1; D006801:Humans; D015398:Signal Transduction / Q000502:physiology
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors